Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin

Zhen Wang, Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai, People's Republic of ChinaAbstract: Coronary heart disease (CHD) is the leading cause of death worldwide. The efficacy and safety of statins in primary and secondary prevention of CHD is confirmed in several large stu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang Z, Ge JB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Rosuvastatin Chinese younger elderly dyslipidemia atherosclerosis Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/5d4af42d90c74a8e8128587461e6b238
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5d4af42d90c74a8e8128587461e6b238
record_format	dspace
spelling	oai:doaj.org-article:5d4af42d90c74a8e8128587461e6b2382021-12-02T00:58:35ZManaging hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin1178-1998https://doaj.org/article/5d4af42d90c74a8e8128587461e6b2382013-12-01T00:00:00Zhttps://www.dovepress.com/managing-hypercholesterolemia-and-preventing-cardiovascular-events-in--peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Zhen Wang, Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai, People's Republic of ChinaAbstract: Coronary heart disease (CHD) is the leading cause of death worldwide. The efficacy and safety of statins in primary and secondary prevention of CHD is confirmed in several large studies, and rosuvastatin is the latest statin on market. We review the published literature on rosuvastatin in Chinese people. The pharmacokinetics of rosuvastatin in Chinese is somewhat different from that in Caucasians, but this does not influence the linear relationship between dosage and efficacy and with no drug accumulation. Rosuvastatin 5–20 mg/day is effective and safe in decreasing low-density lipoprotein cholesterol in both younger and elderly patients with hypercholesterolemia, even in very elderly patients. Rosuvastatin also shows anti-inflammatory and antiatherosclerosis features, such as reducing carotid intima-media thickness and plaque area. Rosuvastatin can also improve the prognosis of Chinese CHD patients, such as in the case of acute myocardial infarction. Its adverse-event rate is low and comparable to other statins. In conclusion, rosuvastatin is effective and safe for younger or elderly Chinese patients.Keywords: rosuvastatin, Chinese, younger, elderlyWang ZGe JBDove Medical PressarticleRosuvastatinChineseyoungerelderlydyslipidemiaatherosclerosisGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 9, Pp 1-8 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Rosuvastatin Chinese younger elderly dyslipidemia atherosclerosis Geriatrics RC952-954.6
spellingShingle	Rosuvastatin Chinese younger elderly dyslipidemia atherosclerosis Geriatrics RC952-954.6 Wang Z Ge JB Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
description	Zhen Wang, Junbo GeDepartment of Cardiology, Zhongshan Hospital, Shanghai, People's Republic of ChinaAbstract: Coronary heart disease (CHD) is the leading cause of death worldwide. The efficacy and safety of statins in primary and secondary prevention of CHD is confirmed in several large studies, and rosuvastatin is the latest statin on market. We review the published literature on rosuvastatin in Chinese people. The pharmacokinetics of rosuvastatin in Chinese is somewhat different from that in Caucasians, but this does not influence the linear relationship between dosage and efficacy and with no drug accumulation. Rosuvastatin 5–20 mg/day is effective and safe in decreasing low-density lipoprotein cholesterol in both younger and elderly patients with hypercholesterolemia, even in very elderly patients. Rosuvastatin also shows anti-inflammatory and antiatherosclerosis features, such as reducing carotid intima-media thickness and plaque area. Rosuvastatin can also improve the prognosis of Chinese CHD patients, such as in the case of acute myocardial infarction. Its adverse-event rate is low and comparable to other statins. In conclusion, rosuvastatin is effective and safe for younger or elderly Chinese patients.Keywords: rosuvastatin, Chinese, younger, elderly
format	article
author	Wang Z Ge JB
author_facet	Wang Z Ge JB
author_sort	Wang Z
title	Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
title_short	Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
title_full	Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
title_fullStr	Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
title_full_unstemmed	Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin
title_sort	managing hypercholesterolemia and preventing cardiovascular events in elderly and younger chinese adults: focus on rosuvastatin
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/5d4af42d90c74a8e8128587461e6b238
work_keys_str_mv	AT wangz managinghypercholesterolemiaandpreventingcardiovasculareventsinelderlyandyoungerchineseadultsfocusonrosuvastatin AT gejb managinghypercholesterolemiaandpreventingcardiovasculareventsinelderlyandyoungerchineseadultsfocusonrosuvastatin
_version_	1718403384895078400

Managing hypercholesterolemia and preventing cardiovascular events in elderly and younger Chinese adults: focus on rosuvastatin

Ejemplares similares